Comparison of Anti-tumor Properties of the Cell walls of Saccharomyces Cerevisiae and Saccharomyces Boulardi Probiotics, individually and in Combination with Iron Nanoparticles on K562 Cancer cell line
,
Abstract
Background: Chronic myeloid leukemia is a common cancer in human and chemical therapy is a routine method for treatment that has some side effects. So the goal of this study was the use of natural compound such as cell wall obtained from Saccharomyces cerevisiae (S. cerevisiae) and Saccharomyces boulardi (S. boulardi) and iron nanoparticles on the growth inhibition of K562 cell line.Methods: For cell wall preparation both yeast were cultured in a basic medium at aerobic condition and 28 °C. Then the medium was centrifuged and precipitant washed with sterile buffer and the cells disrupted by sunicator. Also iron nanoparticles were prepared by biological method. Anti cancer property of different concentrations of the yeasts cell wall with iron nanoparticles were assayed by MTT and electrophoresis methods.Results: The results showed that S. boulardi cell wall significantly (p=0.029) inhibits the growth of K562 cell line compared to S. cerevisiae. Also iron nanoparticles significantly (p=0.021) inhibit K562 cell line. Results revealed that combination the iron nanoparticles with both yeasts cell wall decreased anti cancer property but this was not significant at the level of p<0.05.Conclusion: Based on this finding it should be concluded that combination of iron nanoparticles with Saccharomyces cell walls could inhibit the growth of K562 cell line in vitro. But these anti cancer properties would warrant further study on the clinical application of yeast cell wall.Zarin-Far N, Sarmadian H, Esmaeeli A, 2012: role of pro- biotics in preventing colitis and diarrhea caused by antibi- otics. Journal of Southern Medicine, Bushher University of Medical Sciences [Persian].
Saadat M, Roodbari-Mohammadi Sh, Yadegari M, Es- kandari M, khavari-nejad Rl. evaluation and comparison of anti-bacterial activity of catechins, nanoparticles of zinc oxide, ethelene diamine tetra acetic acid on standard strain of pseu- domonas aeruginose. Journal of Gahrum University of Med- ical Sciences, 2012: 10th year, number 18, pp 13 [Persian].
Molaee-Kandelusi M, Mirzaee F, Shakoori M, Navid shar B. probiotic effect of Saccharomyces cerevisiae and organic acid on growth performance and blood parameters in Broil- ers. 1st National Congress of Modern Agricultural Science and Technology. 2011. [Persian].
Agrawal P.B. and Pandi A.B. Isolation of alphaglucosidase from Saccharomyces cerevisiae: Cell disruption and adsorp- tion. Biochemical Engineering Journal. 2011: 15: 37-45.
A.K. Gupta , M. Gupta. Biomaterials. 2005:26, 3995.
Alexiou, W. Arnold, R. J. Klein, F. G. Parak, P. Hulin, C. Bergemann, W. Erhardt, S. Wagenpfeil, and A. S. Lubbe, Cancer Res. 2000: 60, 6641.
Andreas S lubbe. clinical Applications of Magnetic Drug Targeting. Journal of surgical Research 95/2001/200-206.
Brannon-Peppas L, Blanchette JO. Nanoparticle and target- ed systems for cancer therapy. Adv. Drug Deliv. Rev. 2004: 56(11), 1649–1659
Bujalance C, M oreno E, J imenez- V alera M, R uiz- B ravo A. A probiotic strain of Lactobacillus plantarum stimulates lymphocyte response- Int J Food Microbiol. 2007;113(1):28- 34.
C.Berry, A. S. G. Curtis, J. Phys. D: Appl. Phys. 2003: 36, R198 .
Campieri, Goonchetti. Bacteria as the cause of uncreative colitis. Gut. 2001: 48(1): 132-35.
Castagliuolo I., Riegler M F, Valenick L, LaMont JT, Pot- houlakis C. Saccharomyces boulardii protease.
Chin-Feng L, Tzu-Ming P. In Vitro Effects of Lactic Acid Bacteria on Cancer Cell Viability and Antioxidant Activity. Journal of Food and Drug Analysis. 2010: 18: 77-86.
Cortes J. :Natural history and staging of chronic mye- logenous leukemia. HematolOncolClin North Am. 2004: 18:569–84.
Croos ML. Microbes versus microbes: immune signals generated by probiotic lactobacilli and their role in protection against microbial pathogens, FEMS Immunology and Medi- cal Microbiology. 2002: 34,245-253.
Davis ME, Chen ZG, Shin DM. Nanoparticle therapeu- tics: an emerging treatment modality for cancer. Nat. Rev. Drug Discov. 7(9), 771–782 (2008).
Deininger M.V, Goldman J.M and Melo J.V. (2000) Themolescular biology or chronic myeloid Leukemia. Blood, 96: 3343-3356.distinctcaspase cascades in death recepto and stress-activated apoptosis Ex Cell Res; 256:27-33.
Dreher K L. Health and environmental impact of nano- technology: Toxicology calassessment of manufactured nan- oparticles. Toxicol Sci. 2004;77:3-5.
Dura’n N, Marcato PD, De S, Alves O, Esposito E. An- tibacterial effect of silver nanoparticles produced by fungal process on textile fabrics and their effluent treatment. J Bi- omed Nanotechnol ;3:203-8.
Ekert H, Jurk I.H, Waters K.D and Tiedemann K. Prophy- lactic cotrimoxazole and lactobacilia preparation in neutro- penicpatiens Medical and pediatric oncology, 1980: 8:47-51.
Elbashir S.M, Martinez J, Patkaniowska A, Lendeckel W and Tuschl T. Functional anatomy of siRNAs for mediating efficient RNAi in Drosophila melanogaster embryo lysate. European Molecular Biology Organization Journal; 2001: 20: 6877-6888.
G. Ciofani, C. Riggio, V. Raffa, A. Menciassi, and A. Cuschieri, Med. Hypotheses. 2009: 73, 80.
Ghoneum M, Nariman K, Noaman BE, Tolentino L. Sac- charomyces cerevisiae, the Baker s Yeast, suppresses the growth of Ehrlich carcinoma-bearing mice, Cancer Immunol- ogy and Immunotherapy. 2008:57:581-592.
Gill HS, Rutherfurd KJ, Prasad J, Gopal PK. Enhance- ment of natural and acquired immunity by Lactobacillus rhamnosus (HN001), Lactobacillus acidophilus (HN017) and Bifidobacteriumlactis (HN019). Br J Nutr,2000;83(2):167-76
Gottesman MM. Mechanisms of cancer drug resistance. Annu. Rev. Med.2002: 53, 615–627 .
Hardman R A. Toxicological review of quantum dots: Toxicity depends on physic-chemical and environmental fac- tors. Environ Health Perspect. 2005;114:165-172.
Hart A.L, Kamm M.A. Mechanism of action of probiotics. Recent advances. Inflammatory Bowel Diseases, 2009:15: 300-310.
Kankaanpaa PE, Yang B, Kallio HP, et al. Influence of probiotic supplemented infant formula on composition of plasma lipids in atopic infants. J NutrBiochem. 2002: 13(6): 364-9.
Kellycp,lamont GT.Clostridumdifficile More Difficult Than Ever. N Eng1 J Med. 2008:359:1932-40.
Kirjavainen PV, Salminen SJ, Isolauri E. Probiotic bac- teria in the management of atopic disease : underscoring the importance of viability. J Pediatr GastrenterolNutr. 2003: 36(2): 223-7. -73.ses in immunologically intact and immu- nocompromised mice.
Kontiokari T, Laitinen J, jarvi L, et al. Dietary factors protecting women form urinary tract infection. Am JClinNutr .2003: 77(3): 600-4.
KooO.M, Rubinstein I, Onyuksel H.2005. Role of nano- technology in targeted drug delivery and imaging: a concise review. Nanomed.: Nanotechnol.,Biol.Med.,vol.1(3),p.193.
Kukuowska-Latallo J.F, Candido K.A, Zhengyic. Nano- particle targeting of anticancer drag improves therapeutic re- sponse in animal model of human epithelial cancer. Cancer. Res. 2005: 65: 5317-5324.
Lee A., Whyte M.K.B., Haslett C. Inhibition of apopto- sis and prolongation of neutrophil functional longevity by inflammatory mediators. Jun-Yi Leu-Institute of molecular Biology, 1993: 54: 283-288.
Li P, Li J, Wu C, Wu Q. Synergistic antibacterial effects of Lactam antibiotic combined with silver nanoparticles. J Nanotechnol. 2005:16:1912-1917.
Magnelli P, Cipollo J.F, Abeijon C. (2011) A refined method for the determination of Saccharomyces cerevisiae cell wall composition and beta-(1,6)- Dglucan fine structure. Analytical Biochemistry, 301: 136-150.
Maroufi B, Sussan Ardestani K, Kariminia A and Nade- rimanesh H. (2005) The Effect of Vitamin E on Splenocytes Apoptosis of Gamma-Irradiated BALB/c Mice. Iranian Jour- nal of Allergy, Asthma and Immunology; 4: 77-82.
Matsumara K, Kitazawa H, Itoh T,. Interferon induction by murine peritoneal macrophage stimulated with Lactobacil- lus gasseri. Animal SciTechnol 1992; 63: 1157-59.
Peer D, Karp JM, Hong S, Farokhzad OC, Margalit R, Langer R. Nanocarriers as an emerging platform for cancer therapy. Nat. Nanotechnol. 2(12), 751–760 (2007)
Q. A. Pankhurst, J. Connolly, S. K. Jones, J. Dobson, J. Phys. D: Appl. Phys. 36, R167 (2003) .
Reid G. Probiotics for urogenital health .NutrClin Care 2002; 5(1): 3-8.
Roenfeldt V, Benfeldt E, Nielsen SD, et al. Effect of pro- biotic lactobacillus strains in children with atopic dermatitis ClinImmunol 2003; 111(2): 389-95.
S. Lubbe, C. Alexiou, C. Bergemann, J. Surg. Res. 95, 200 (2001) .
Schrezenmeir J, de Vrese M. Probio tics, prebiotics, syn- biotics: approaching a definition. Am J Clin Nutr2001;73(2 Suppl):361S-364S.
Stanton C, Gardiner G, Meehan H, et al. Market potential for probiotics. Am J ClinNutr 2001; 73(2): 476S-83S
Tukmechi A, RahmatiAndani H.R, Manaffar R, Sheikhza- deh N. (2011) Dietary administration of beta-mercapto-etha- nol treated Saccharomyces cerevisiae enhanced the growth, innate immune response and disease resistance of the rainbow trout, Oncorhynchusmykiss. Fish and Shellfish Immunology, 30: 923-928.
Wollowski I, Rchkemmer G., Beatricel L. Poll Z. (2001) Protective role of probiotics and prebiotics in colon cancer. Am J clinNutr; 73: 4515-55.
Y. Goon, L. M. H. Lai, M. Lim, P. Munroe, J. J. Gooding, R. Amal, Chem. Mat. 21, 673 (2009) inhibits the effects of Clostridium difficile toxins A and B in human colonic muco- sa. Infect Immun 1999; 67: 302-307.
Zhang L, Gu FX, Chan JM, Wang AZ, Langer RS, Farokhzad OC. Nanoparticles in medicine: therapeutic ap- plications and developments. Clin. Pharmacol. Ther. 83(5), 761–769 (2008).
| Files | ||
| Issue | Vol 6 No 4 (2014) | |
| Section | Original Articles | |
| Keywords | ||
| Saccharomyces cerevisiae S. boulardi iron nanoparticles Growth inhibition K562 cell line | ||
| Rights and permissions | |
|
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
